ELOQUENT-2: Addition of Elotuzumab to Len/Dex Extends PFS in Relapsed/Refractory Myeloma

May 29-June 2, 2015; Chicago, Illinois
Results from a randomized phase III trial investigating the addition of the mAB elotuzumab to lenalidomide and dexamethasone in patients with relapsed/refractory MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 393 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Expert commentary with practical insights on the recent FDA approval and use of acalabrutinib in CLL from Clinical Care Options (CCO)

Nicole Lamanna, MD Released: January 10, 2020

This archived CE-certified Clinical Care Options webcast presents optimal nursing strategies for the management of patients with multiple myeloma.

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Program Director
Joseph Tariman Headshot Joseph D. Tariman, PhD, RN, ANP-BC, FAAN
Program Director
Registered Nurses: 1.0 Nursing contact hour Released: January 6, 2020 Expiration: January 5, 2021

A summary slideset with a European perspective on highlights of key data in chronic lymphocytic leukemia and lymphomas from ASH 2019.

Released: December 23, 2019

A summary slideset with a European perspective on highlights of key data in acute and chronic leukemias from ASH 2019.

Released: December 23, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?